{"id":1014851,"date":"2026-10-28T19:16:27","date_gmt":"2026-10-28T23:16:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\/"},"modified":"2026-10-28T19:16:27","modified_gmt":"2026-10-28T23:16:27","slug":"intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\/","title":{"rendered":"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"
\n

CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc.<\/a> (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it awarded inducement grants on October 26, 2026, to its Executive Vice President and Chief Medical Officer, Jing Marantz, M.D., Ph.D., as a material inducement to employment.<\/p>\n

The inducement grants consisted of (1) non-qualified stock options to purchase 275,061 shares of Intellia\u2019s common stock with an exercise price of $11.26 per share (the \u201coption award\u201d), the closing price of Intellia\u2019s common stock as reported by Nasdaq Global Market on October 26, 2026, with one-third of the options underlying the option award vesting on the first anniversary of the grant date and the remainder vesting monthly thereafter until fully vested on the third anniversary of the grant date and (2) time-based restricted stock units (\u201cRSUs\u201d) for 199,822 shares of Intellia\u2019s common stock (the \u201cRSU award\u201d), with one-third of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the grant date.<\/p>\n

All equity vesting is subject to Dr. Marantz\u2019s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.<\/p>\n

All of the above-described awards were granted outside of Intellia\u2019s stockholder-approved equity incentive plans pursuant to Intellia\u2019s 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024. These awards were approved by a majority of the independent directors of Intellia\u2019s board of directors as a material inducement to Dr. Marantz\u2019s entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n

\n About Intellia Therapeutics<\/strong>\n <\/p>\n

Intellia Therapeutics, Inc.\u00a0(Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company\u2019s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at\u00a0intelliatx.com<\/a> and follow us @intelliatx<\/a>.<\/p>\n

\n
\n Investor Contact:<\/em>
\n <\/strong>
\n
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com<\/a><\/p>\n

\n
\n Media\u00a0Contact:<\/em>
\n <\/strong>
\n
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicomms.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it awarded inducement grants on October 26, 2026, to its Executive Vice President and Chief Medical Officer, Jing Marantz, M.D., Ph.D., as a material inducement to employment. The inducement grants consisted of (1) non-qualified stock options to purchase 275,061 shares of Intellia\u2019s common stock with an exercise price of $11.26 per share (the \u201coption award\u201d), the closing price of Intellia\u2019s common stock as reported by Nasdaq Global Market on October 26, 2026, with one-third of the options underlying the option award vesting on the first anniversary of the … <\/p>\n

Continue reading “Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1014851","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it awarded inducement grants on October 26, 2026, to its Executive Vice President and Chief Medical Officer, Jing Marantz, M.D., Ph.D., as a material inducement to employment. The inducement grants consisted of (1) non-qualified stock options to purchase 275,061 shares of Intellia\u2019s common stock with an exercise price of $11.26 per share (the \u201coption award\u201d), the closing price of Intellia\u2019s common stock as reported by Nasdaq Global Market on October 26, 2026, with one-third of the options underlying the option award vesting on the first anniversary of the … Continue reading "Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-28T23:16:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTM0NSM3OTIxODc2IzIwMjkyMDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-10-28T23:16:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\\\/\"},\"wordCount\":382,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NTM0NSM3OTIxODc2IzIwMjkyMDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\\\/\",\"name\":\"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NTM0NSM3OTIxODc2IzIwMjkyMDE=\",\"datePublished\":\"2026-10-28T23:16:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NTM0NSM3OTIxODc2IzIwMjkyMDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NTM0NSM3OTIxODc2IzIwMjkyMDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\/","og_locale":"en_US","og_type":"article","og_title":"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it awarded inducement grants on October 26, 2026, to its Executive Vice President and Chief Medical Officer, Jing Marantz, M.D., Ph.D., as a material inducement to employment. The inducement grants consisted of (1) non-qualified stock options to purchase 275,061 shares of Intellia\u2019s common stock with an exercise price of $11.26 per share (the \u201coption award\u201d), the closing price of Intellia\u2019s common stock as reported by Nasdaq Global Market on October 26, 2026, with one-third of the options underlying the option award vesting on the first anniversary of the … Continue reading \"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-28T23:16:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTM0NSM3OTIxODc2IzIwMjkyMDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-10-28T23:16:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\/"},"wordCount":382,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTM0NSM3OTIxODc2IzIwMjkyMDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\/","name":"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTM0NSM3OTIxODc2IzIwMjkyMDE=","datePublished":"2026-10-28T23:16:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTM0NSM3OTIxODc2IzIwMjkyMDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTM0NSM3OTIxODc2IzIwMjkyMDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1014851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1014851"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1014851\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1014851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1014851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1014851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}